Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

DECEMBER 26, 2021

In furtherance of its program, the Company filed US Provisional Patent Application No. “Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

DECEMBER 9, 2021

The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. Simister have extensive backgrounds in stroke management as well as clinical care and stroke research.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 17, 2021

Jazz said it expects to generate 65% of 2022 revenues from products that have been launched or acquired since 2019. As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S. 13.40 – $14.70.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Transaction expected to close in June 2022 , following anticipated shareholder approval. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

MAY 10, 2022

11 May 2022. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions. Here’s the Uni of Sydney press release.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

JANUARY 12, 2022

11, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. LAS VEGAS, Jan.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. Trial of Psilocybin Versus Escitalopram for Depression , 384 New England J.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Tucker brings to Goldfinch Bio over 30 years of clinical experience across a variety of therapeutic areas and early- and late-stage companies. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JANUARY 19, 2022

January 17, 2022. – January 17, 2022) – Psygen Industries Ltd. received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “). received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. Together with Maya, we will be able to first and foremost optimize treatment for communities left behind in the prescription-based model. ABOUT MAYA.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

SEPTEMBER 23, 2022

SB 57 – which passed both houses – would have created a pilot program for overdose prevention sites in San Francisco, Oakland, and Los Angeles as an evidence-based intervention to curb drug overdose deaths. September 1, 2022. ABOUT MAPS.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022. Fortified Balance Sheet. On September 30, 2021, Can-Fite had approximately $13.3 Financial Results.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Applicants must also authorize their training program to conduct a criminal background check. Conducting Psilocybin Integration (14 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

JUNE 19, 2022

Although more mental health services are provided by social workers than all other disciplines combined, no other social work program in the country is engaged in this type of work that Dr. Davis and his colleagues are undertaking,” said College of Social Work Dean Tom Gregoire. Jason Slot.

Education 52

Education Research and Development Therapy Clinical Trials 52

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Dr. Jacobs, who most recently served as CSO of Ardelyx, Inc.,

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

NOVEMBER 29, 2021

In short: IMO COMPASS Pathway is one of the most undervalued & impactful biotech stocks out there – and atai is committed to being the global leader in novel mental health treatments. We think the COMPASS Phase 2b trial for Treatment-Resistant Depression (TRD) is a total game-changer. Published on November 30, 2021.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

MARCH 3, 2022

If everything works out in the production and research phase, there is a clause in the license that will allow it to be expanded to clinical trials. The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety. This would add to the wave of research beginning in the U.S. and Europe.

Research and Development 52

Research and Development Medicine Clinical Trials Microdosing 52

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. This study highlights CBD and its active metabolite, 7-OH-CBD, as potential preventive agents and therapeutic treatments for SARS-CoV-2 in the early stages of infection.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

NOVEMBER 15, 2021

“This is an exciting time at Virpax, and we believe that all of our product candidates have the potential to deliver significant improvements and benefits to currently existing treatment options,” concluded Mr. Mack. RECENT DEVELOPMENTS. On July 30, 2021, Virpax announced the appointment of Gerald W. Bruce and Michael F.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. The combined company expects to receive up to $287.5

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

DECEMBER 21, 2021

Prakat swiftly modernizes legacy business hardware, software programs, and downloadable apps. The school’s new location will be opening up in Q1 of 2022 to further ease the shortage and tension of much-needed healthcare workers. Ignite products are ecologically responsible and do not require additional wastewater treatment.

Research and Development 52

Research and Development Supply Chain Data Business 52